- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04679740
Resorbable Magnesium Scaffolds Registry
May 16, 2023 updated by: Biotronik AG
RMS (Resorbable Magnesium Scaffolds) Registry
The registry follows the ESC/EACTS guideline and further investigates the clinical performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (IFU).
Study Overview
Study Type
Observational
Enrollment (Anticipated)
1106
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dimitra Antonopoulou, M.Sc.
- Phone Number: 0041448645753
- Email: dimitra.antonopoulou@biotronik.com
Study Locations
-
-
-
Bad Segeberg, Germany, 23795
- Recruiting
- Heart Center Segeberger Kliniken
-
Contact:
- Ralph Toelg, MD
-
Kempten, Germany
- Recruiting
- Herz-und Gefäßzentrum Oberallgäu-Kempten
-
Contact:
- Jan Torzewski, Prof
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with symptomatic coronary artery disease needing the treatment of de novo native coronary artery lesions
Description
Inclusion Criteria:
- According to the IFU
Exclusion Criteria:
- According to the IFU
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target Lesion Failure (TLF)
Time Frame: 12 months
|
The primary endpoint will be Target Lesion Failure (TLF) at 12 months.
TLF is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave MI, or clinically driven Target Lesion Revascularization (TLR).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically driven Target Lesion Revascularization (TLR)
Time Frame: 12 months
|
According to ARC-2 definition
|
12 months
|
Cardiovascular Death (CD)
Time Frame: 12 months
|
According to ARC-2 definition
|
12 months
|
Target Vessel MI
Time Frame: 12 months
|
According to ARC-2 definition
|
12 months
|
Definite scaffold thrombosis
Time Frame: 12 months
|
According to ARC-2 definition
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stefano Galli, MD, Centro Cardiologico Monzino
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 18, 2020
Primary Completion (Anticipated)
December 1, 2026
Study Completion (Anticipated)
December 1, 2026
Study Registration Dates
First Submitted
December 17, 2020
First Submitted That Met QC Criteria
December 17, 2020
First Posted (Actual)
December 22, 2020
Study Record Updates
Last Update Posted (Actual)
May 18, 2023
Last Update Submitted That Met QC Criteria
May 16, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- C1908
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The primary outcome data will be shared after the publication of it.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Magmaris
-
Spanish Society of CardiologyCompletedCoronary Artery DiseaseSpain
-
Charite University, Berlin, GermanyTerminatedAcute Coronary Syndrome | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionGermany
-
Biotronik AGActive, not recruitingCoronary Artery DiseaseHong Kong, Belgium
-
Aarhus University Hospital SkejbyActive, not recruiting
-
Universitaire Ziekenhuizen KU LeuvenUniversitair Ziekenhuis Brussel; Ziekenhuis Oost-Limburg; Centre Hospitalier... and other collaboratorsUnknown
-
University Hospital, GenevaTerminated
-
Biotronik AGCBCC-VIBGYOR Research Pvt. Ltd.SuspendedCoronary Artery DiseaseIndia